MANIPALHOSManipal Health Enterprises Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Manipal Health Enterprises Limited operates hospitals in India. The company offers services, such as multi-specialty tertiary and quaternary care through its network of hospitals. Its services include accident and emergency care, cancer care, cardiology, organ transplants, obstetrics and gynaecology, neurology, nephrology, orthopaedics, proctology, rheumatology, and urology. The company also offers medical services, including robotic spine surgery, bariatric surgery, head and neck surgery, liver transplantation, dialysis, laparoscopic surgery, organ transplant, orthopaedic robotic surgery, spine care, and clinics for conditions like epilepsy, chronic pain, and diabetes. Additionally, It offers home care, woman and child care centre, an insurance helpdesk, and international patient services. The company also delivers outpatient treatment, diagnostics, and advanced clinical care through its hospital network, and collaborates with foundations and NGOs to offer healthcare services to underserved populations. The company was founded in 1991 and is headquartered in Bengaluru, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on MANIPALHOS — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 18.0% YoY
- • Profit growth: 27.7% YoY
- • 1-month vs NIFTY: +7.3% relative
- • Distance from 52-week high: 12.0% below high
- • Max drawdown (1y): 11%
- • Liquidity: ₹132.2 cr avg turnover
Bull case
- • Revenue growth: 18.0% YoY
- • Profit growth: 27.7% YoY
- • 1-month vs NIFTY: +7.3% relative
- • Distance from 52-week high: 12.0% below high
Bear case
- • Recently listed — limited trading history, scores are provisional
- • ROCE: 9.4%
- • Debt/Equity: 1.46
- • Insufficient price history
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Recently listed — limited trading history, scores are provisional
- • ROCE: 9.4%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹29.60). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.